MediciNova, Inc. 2022 Form 10-K Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on therapeutics for serious diseases with unmet medical needs. The filing covers the fiscal year ended December 31, 2022, and was filed February 16, 2023. The company has no products approved for commercial sale and has no product sales revenue.
The primary development programs are MN-166 (ibudilast), targeting neurological, addiction, oncology and respiratory indications, and MN-001 (tipelukast), targeting NAFLD and fibrotic diseases. MN-029 (denibulin) remains in the pipeline for solid tumors. The MN-221 (bedoradrine) license was terminated in October 2022.
Key financial metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0.0 million | $4.0 million | Down $4.0 million |
| Research, development and patent expense | $9.1 million | $8.5 million | Up $0.6 million |
| General and administrative expense | $5.5 million | $5.7 million | Down $0.2 million |
| Operating loss | $14.6 million | $10.2 million | Loss increased |
| Net loss | $14.1 million | $10.1 million | Loss increased $3.9 million |
| Net loss per share | $0.29 | $0.21 | Loss per share increased |
| Net cash used in operating activities | $12.9 million | $9.4 million | Use increased $3.5 million |
| Cash and cash equivalents | $18.5 million | $71.4 million | Down $52.9 million |
| Investments | $40.0 million | None reported | Increased |
| Working capital | $55.8 million | Not clearly stated in the filing text | Not clearly stated |
Interest income increased to $0.8 million from $0.1 million, primarily because of higher interest rates on cash and certificates of deposit. Other expense increased to approximately $247,000 from $59,000, including early-disposal penalties on certificates of deposit, interest expense and foreign-currency transaction losses.
At December 31, 2022, total assets were $74.2 million, total liabilities were $3.9 million and stockholders’ equity was $70.2 million. The company reported no debt balance in the consolidated balance sheet. Lease liabilities totaled $0.7 million, and aggregate future lease commitments were $0.7 million.
Material changes versus the prior comparable period
- Revenue fell to zero because the company received two Genzyme milestone payments totaling approximately $4.0 million in 2021 and none in 2022.
- Research, development and patent expense increased 7% to $9.1 million, mainly due to higher MN-166 and MN-221-related expenses. MN-166 external development expense was $6.4 million.
- Net loss increased from $10.1 million to $14.1 million, despite lower general and administrative expense, primarily reflecting the loss of prior-year milestone revenue and higher development spending.
- Operating cash use increased to $12.9 million. Investing cash use of $40.0 million primarily reflected purchases of bank certificates of deposit with maturities of seven to 13 months.
- Cash and cash equivalents declined substantially, but the company held $40.0 million of investments at year-end. Financing cash flow was only $8,000 in 2022, compared with $20.8 million in 2021 from equity issuance and option exercises.
- Shares outstanding increased modestly to 49.0 million from 49.0 million at year-end 2021. Approximately 8.0 million stock options were outstanding at year-end, with a weighted-average exercise price of $5.55.
- The company terminated the MN-221 license with Kissei and purchased 7.15 kilograms of active pharmaceutical ingredient for JPY114.4 million. It reported no further financial obligations to Kissei under the terminated license.
Clinical, strategic and operational developments
- MN-166 COVID-19 Phase 2 results announced in June 2022 showed statistically significant improvement versus placebo for freedom from respiratory failure at Day 7 and hospital discharge. The filing describes two placebo-group deaths and no MN-166-group deaths, but these results remain clinical-development data and do not represent regulatory approval.
- MN-001 entered a Phase 2 trial in July 2022 for patients with NAFLD, type 2 diabetes and hypertriglyceridemia. The planned study is expected to enroll approximately 40 patients and evaluate liver fat content and fasting triglycerides over 24 weeks.
- Ongoing programs include Phase 2b/3 development of MN-166 in ALS, a Phase 3 degenerative cervical myelopathy study, a Phase 2b chemotherapy-induced peripheral neuropathy study, a glioblastoma study and an alcohol-use-disorder Phase 2b study.
- The company plans to pursue strategic alliances, government or grant-funded studies and potential out-licensing arrangements to support development and commercialization.
- MediciNova has no internal sales or marketing capabilities and expects to rely on strategic partners if any product is approved.
Liquidity, outlook and risks
Management expects research and development expense to increase moderately in 2023 and expects continued significant operating losses for the foreseeable future. The company estimates 2023 operating cash needs of approximately $21.2 million and states that available working capital is expected to fund operations at least through the end of 2024, assuming spending remains at a similar level in 2024, including inflation.
The company states that additional capital may be required to continue operations and complete development or commercialization. Its September 2022 shelf registration permits offerings of up to $200.0 million of securities. The ATM agreement permits common-stock sales up to an aggregate offering price of $75.0 million, with $64.7 million registered under the current prospectus supplement; no ATM shares were sold in 2022 or 2021.
- The company has incurred significant cumulative losses: accumulated deficit was $407.1 million at December 31, 2022.
- There is no assurance that additional financing, partnerships or licensing transactions will be available on acceptable terms or at all. Failure to obtain funding could require delays, reductions or discontinuation of development programs.
- All product candidates remain subject to clinical-trial, regulatory, safety, manufacturing and commercialization risks. Positive early or interim results may not predict later results or regulatory approval.
- The company relies on third parties for clinical trials, manufacturing and other development activities, creating risks related to performance, supply, quality, cost and timing.
- Intellectual-property protection is limited for certain compounds. The company does not have composition-of-matter patent protection for the active pharmaceutical ingredients in MN-166, MN-001 or MN-221, although it has method-of-use and other patents.
- Clinical-trial accruals were $1.5 million at year-end and depend on estimates of vendor progress and services performed.
- The company has approximately $276.6 million of federal and $182.9 million of California net operating loss carryforwards, but their utilization may be limited by ownership-change rules. A full Section 382/383 analysis has not been completed since 2011.
- COVID-19 and other public-health events may continue to affect enrollment, supply chains, third-party contractors, liquidity and operations.
- The common stock is subject to substantial volatility, potential dilution from future equity offerings and possible Nasdaq or Tokyo Stock Exchange listing-compliance risks.
Important facts for investors to verify
- Reconcile the company’s stated ability to fund operations through at least the end of 2024 with projected 2023 operating cash needs of $21.2 million, future clinical spending and potential milestone obligations.
- Review the status, enrollment, funding source, endpoints and next regulatory milestones for the MN-166 ALS, alcohol-use-disorder, glioblastoma and respiratory programs and the MN-001 NAFLD program.
- Assess whether the positive COVID-19 Phase 2 findings are being pursued commercially or in additional pivotal studies, particularly given the changing treatment environment.
- Monitor additional equity financing under the $200.0 million shelf registration or $75.0 million ATM agreement and the resulting dilution risk.
- Verify the consequences of terminating the MN-221 license, including the strategic value of the remaining program and the treatment of the purchased active pharmaceutical ingredient.
- Evaluate patent expiration dates, method-of-use coverage and generic-competition exposure for MN-166 and MN-001.
- Review clinical-trial accrual estimates, future license milestones of up to $26.5 million and the company’s reliance on external vendors.
- Confirm that no products are approved for sale and that the company’s future revenue outlook depends on successful clinical development, regulatory approval and potential partnering or out-licensing transactions.